91
91
Nov 6, 2013
11/13
by
CNBC
tv
eye 91
favorite 0
quote 0
lots of drugs but only one fda regulated quality standard. we think that's what the new law may accomplish and we're looking forward to that. >> okay. but we have seen instances where you break open the vial, where there's been horrible -- there's been deaths. >> well, there's been deaths when people have injected drugs that have compounded. there has been blindness from drugs injected in the eye. this is why we need one quality standard. we need the fda to regulate this and that's what i think the new compounding legislation, if it gets passed, will actually do, and it'll make things safer. >> now, just circle back, it's pertinent now. the diabetic, you're saying that's ready. that's one of the things -- you're saying they're just waiting. you're ready to go the moment that thing -- >> we are ready to go but we still have to go through the approval process. we've submitted -- >> what are those people taking right now? >> they're using lucentis, it's been approved. it ahead of us. there's some opportunity out there for people to get treated.
lots of drugs but only one fda regulated quality standard. we think that's what the new law may accomplish and we're looking forward to that. >> okay. but we have seen instances where you break open the vial, where there's been horrible -- there's been deaths. >> well, there's been deaths when people have injected drugs that have compounded. there has been blindness from drugs injected in the eye. this is why we need one quality standard. we need the fda to regulate this and that's...
131
131
Nov 5, 2013
11/13
by
CNBC
tv
eye 131
favorite 0
quote 0
and we've announced today we've filed with the fda to ask for approval for that drug. and we could be on the market as early as next year some time. >> i think this is huge. the doctors i deal with on this particular issue adon't know. they're deathly afraid something bad's going to happen. they have nothing for these people. this could be it. >> well, this is a great rescue medication. >> right. that's what i'm talking about. something happens, there's people -- i just don't think people realize how big it is. >> it -- we think it's a very important indication. >> with the time left, i -- we have regeneron on later, i remember the initial regeneron, spinal cord injuries, everybody cares. anything within five years possible here? >> i founded the company based on my interest in spinal cord injury. we know how awful it is. we have a really exciting medication. we just started a clinical trial in people with acute spinal cord injuries. and in preclinical studies, it showed a potential for rescuing spinal cord tissue so they preserve more function later. now, this trial's
and we've announced today we've filed with the fda to ask for approval for that drug. and we could be on the market as early as next year some time. >> i think this is huge. the doctors i deal with on this particular issue adon't know. they're deathly afraid something bad's going to happen. they have nothing for these people. this could be it. >> well, this is a great rescue medication. >> right. that's what i'm talking about. something happens, there's people -- i just don't...
90
90
Nov 5, 2013
11/13
by
CNBC
tv
eye 90
favorite 0
quote 0
they may get fda approval in february. should i hold? >> yes, i want you to hold because this is j & j's partner in this drug and j & j gets 50% and i think they're very excited about it. a little disappointed about j & j today. my charitable trust owns some. let's go to bill in new york, bill? >> caller: hey, jim, navios maritime partners. >> i like the fact that the baltic dry freight index is going up, that makes me like that stock. let's go to elise in maryland. elise? >> caller: hi, jim, you're my rock star stock star. >> i wish i were that good, but thank you. >> caller: you're quite welcome. looking at the negative action with acadia today, it appears no one needs it. can you give me insight? what's up with that? >> that's a good question. that's a very good question because, you know, i felt the parkinson's progress that they made was okay. let me make some calls. i think that's an okay stock. let's go to patrick in kentucky. patrick? >> caller: hey, a big kentucky wildcat boo-yah to ya. >> nice, love the wildcats. what's going o
they may get fda approval in february. should i hold? >> yes, i want you to hold because this is j & j's partner in this drug and j & j gets 50% and i think they're very excited about it. a little disappointed about j & j today. my charitable trust owns some. let's go to bill in new york, bill? >> caller: hey, jim, navios maritime partners. >> i like the fact that the baltic dry freight index is going up, that makes me like that stock. let's go to elise in...
155
155
Nov 7, 2013
11/13
by
CNBC
tv
eye 155
favorite 0
quote 0
>> that's what the fda submission -- >> what the heck is in that? >> a lot of things, but -- >> who reads -- does somebody read that? come on, they're skimmers down there. >> think of the pressure the fda is under, because those patients should be read and fda has to render an opinion within 12 months. >> that's not possible. >> there's a lot of work. but from that, we're very pleased because we submitted the largest clinical program on hypoparathyroidism ever. >> for either of these drugs, we have to be careful because johnson & johnson is out with a drug, are there other uses for these drugs? i was blown away with how bad what happened to johnson & johnson. >> yes, rightfully so. >> very rightfully so, right? >> yeah. so gatix is indicated for adult short bowel syndrome patients dependent on the support, and with expanding the drug to the pediatric population. >> right. that's important because that does bring in more people. >> but also, it's important because some of the kids die in the absence of the treatment like gatix. >> i think some people
>> that's what the fda submission -- >> what the heck is in that? >> a lot of things, but -- >> who reads -- does somebody read that? come on, they're skimmers down there. >> think of the pressure the fda is under, because those patients should be read and fda has to render an opinion within 12 months. >> that's not possible. >> there's a lot of work. but from that, we're very pleased because we submitted the largest clinical program on...
137
137
Nov 12, 2013
11/13
by
CNBC
tv
eye 137
favorite 0
quote 0
they're at the mercy of fda. the seemingly disappointing guidance that initially caused the stock to plummet in after hours trading. why do people do this? priceline is renowned for giving conservative guidance. over the last seven quarters, the company has beaten the midpoint of forecast by 786 basis points. forecasts don't count. price line now has the new ceo jeffrey boyd. miracle worker, steps back from the ceo job but remains the chairman. priceline has the right successor. darren houston takes over january 1st. he's the guy behind booking.com. that's the priceline crown jewel. here's the bottom line. don't be freaked out by the price tag. this is incredibly well run, anointed growth stock downright cheap on the growth basis. you can play with the common stock. the best way is most conservative, deep in the money call options. control more upside while capping your downside. dawn in california. >> caller: first of all, thank you for taking my call and the education you give to all of us home gamers. >> thank
they're at the mercy of fda. the seemingly disappointing guidance that initially caused the stock to plummet in after hours trading. why do people do this? priceline is renowned for giving conservative guidance. over the last seven quarters, the company has beaten the midpoint of forecast by 786 basis points. forecasts don't count. price line now has the new ceo jeffrey boyd. miracle worker, steps back from the ceo job but remains the chairman. priceline has the right successor. darren houston...
234
234
Nov 23, 2013
11/13
by
CNBC
tv
eye 234
favorite 0
quote 1
cholesterol, i think this could spur a huge 2014 if the company can get that accelerated approval from the fda. remember, from bio gen today, expected approvals can give big bumps in these stocks. the four horsemen from the big apocalypse had been wandering in the wilderness. that stay looks to be over. i would buy all four even after these runs as these stocks are going to be anointed as go-to names for the rest of 2013. i need to speak to brian in washington. brian. >> caller: booya, cramer. >> wow, man, you are a player. you're playing. what's up. >> caller: hey, cramer, i would like to wish you of your team and pros on "mad money" the best of holidays. happy holidays to you guys. >> well, everyone's coming to my house for thanksgiving. not. >> caller: that's great. >> unlikely. >> caller: jim. >> yeah. >> caller: the rest of the country we have some great companies here in the northwest. i'm looking at seattle genetics. >> oh, man, i like that stock. we had on last night terrific. i absolutely think that's another stock that could rally into year end. that's a great, great call. and thank
cholesterol, i think this could spur a huge 2014 if the company can get that accelerated approval from the fda. remember, from bio gen today, expected approvals can give big bumps in these stocks. the four horsemen from the big apocalypse had been wandering in the wilderness. that stay looks to be over. i would buy all four even after these runs as these stocks are going to be anointed as go-to names for the rest of 2013. i need to speak to brian in washington. brian. >> caller: booya,...
76
76
Nov 22, 2013
11/13
by
CNBC
tv
eye 76
favorite 0
quote 0
more regulation of the fda, more creation of life science companies? we've had a real boom in ipos. >> yeah, what we're levered to is really the industry and this new movement, this industry cloud movement. as we get more and more life sciences customers using our software, our software gets better and better, and we start to generate unique data about the industry that we can sell back to the industry. so we're -- the thing to know about veeva or industry cloud in general, is it's actually in the very, very early days. it's somewhat a little bit less predictable and quite exciting. >> well, one of the things that i've discovered about legacy systems, they're a bit pernicious. they're deep down in codes for that company. it's expensive to pull out. when a deal is over for the legacy, is that when you do best? because you can't really rip out these legacy systems. >> well, we actually do replace them. but you're right, it's not easy. there has to be a need to do it. there has to be a major need. usually might come from the top in the organization where
more regulation of the fda, more creation of life science companies? we've had a real boom in ipos. >> yeah, what we're levered to is really the industry and this new movement, this industry cloud movement. as we get more and more life sciences customers using our software, our software gets better and better, and we start to generate unique data about the industry that we can sell back to the industry. so we're -- the thing to know about veeva or industry cloud in general, is it's...